Eli Lilly has established itself as the clear leader in the rapidly expanding GLP-1 therapeutic class, with its injectable drugs Mounjaro and Zepbound driving more than $10 billion in combined quarterly revenue. Demand continues to outstrip supply, reflecting the long-term nature of obesity and diabetes treatment and positioning Lilly to capture an increasing share of a market projected to approach $100 billion by 2030. The company’s early investments in manufacturing capacity expansion have helped alleviate previous shortages and underscore its commitment to scaling production to meet sustained global demand.

Analysts forecast Eli Lilly’s earnings to grow by more than 32% year over year, supporting what many expect to be a higher valuation multiple in the months ahead. Despite trading at a price-to-earnings ratio near 50x forward earnings, the stock has experienced even richer valuations in recent years, driven by consistent revenue growth in the GLP-1 portfolio. The company’s gross margin, north of 80%, and double-digit top-line growth rates have underpinned strong free cash flow generation, enabling continued investment in R&D and shareholder returns without eroding balance-sheet strength.

Beyond its current blockbusters, Eli Lilly has multiple late-stage assets expected to reach key regulatory and clinical milestones in 2026. The company has filed for FDA review of orforglipron, an oral GLP-1 agonist that requires no dietary restrictions and could significantly broaden patient adoption of weight-loss therapy. Additionally, late-stage trials are underway for pipeline candidates targeting Alzheimer’s disease, various oncology indications and cardiovascular conditions. Each approval in these high-impact areas would drive incremental revenue streams and further diversify Lilly’s growth drivers beyond its core obesity and diabetes franchises.